Article info

Download PDFPDF

Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19

Authors

  • Maximilian F Konig Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Alfred HJ Kim Division of Rheumatology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA Division of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA Andrew M. and Jane M. Bursky Center of Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Marc H Scheetz Departments of Pharmacy Practice and Pharmacology; Pharmacometrics Center of Excellence, Midwestern University, Chicago College of Pharmacy, and College of Graduate Studies, Downers Grove, Illinois, USA Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Elizabeth R Graef Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Jean W Liew Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • Julia Simard Department of Epidemiology & Population Health; Department of Medicine, Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, California, USA PubMed articlesGoogle scholar articles
  • Pedro M Machado Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK Department of Rheumatology & Queen Square Centre for Neuromuscular Diseases, University College London Hospitals NHS Foundation Trust, London, UK Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK PubMed articlesGoogle scholar articles
  • Milena Gianfrancesco Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Jinoos Yazdany Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Daman Langguth Department of Immunology, Sullivan Nicolaides Pathology, Brisbane, Queensland, Australia PubMed articlesGoogle scholar articles
  • Philip C Robinson The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia PubMed articlesGoogle scholar articles
  • Google scholar articles
  1. Correspondence to Dr Maximilian F Konig, Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA; konig{at}jhmi.edu; Dr Philip C Robinson, The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia; philip.robinson{at}uq.edu.au
View Full Text

Citation

Konig MF, Kim AH, Scheetz MH On behalf of the COVID-19 Global Rheumatology Alliance, et al
Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19

Publication history

  • Received April 21, 2020
  • Revised April 25, 2020
  • Accepted April 27, 2020
  • First published May 7, 2020.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.